Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,032 public trials 2,027 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, Not Recruiting

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Cleveland Clinic Florida Weston, Florida, United States
  • Augusta University- Georgia Cancer Center Augusta, Georgia, United States
View all 53 locations
View Trial Details
Active, Not Recruiting

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

NCT07387471

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +18 more
Locations
  • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 279178 Nagoya, Aichi-ken, Japan
  • Nagoya City University Hospital /ID# 277580 Nagoya, Aichi-ken, Japan
  • University of Fukui Hospital /ID# 279173 Yoshida-gun, Fukui, Japan
  • Kyushu University Hospital /ID# 277582 Fukuoka, Japan
View all 17 locations
View Trial Details
Active, Not Recruiting

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

NCT03888105

Conditions
B-cell Non-Hodgkin Lymphoma (B-NHL), Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Rush University Medical Center Chicago, Illinois, United States
  • University of Iowa Iowa City, Iowa, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Tufts Medical Center Boston, Massachusetts, United States
View all 119 locations
View Trial Details
Active, Not Recruiting

Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia

NCT06323447

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Diffuse Large B Cell Lymphoma, +18 more
Locations
  • University of Hawaii Cancer Center Honolulu, Hawaii, United States
  • Norton Healthcare Cancer Center Louisville, Kentucky, United States
  • Massachussetts General Hospital Boston, Massachusetts, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
View Trial Details
Active, Not Recruiting

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

NCT02978625

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Anaplastic Large Cell Lymphoma, ALK-Positive, +86 more
Locations
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • Keck Medical Center of USC Pasadena Pasadena, California, United States
View all 36 locations
View Trial Details
Active, Not Recruiting

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

NCT04847453

Conditions
Amyloidosis, Immune System Diseases, Immunoglobulin Light-chain Amyloidosis, +11 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
View all 16 locations
View Trial Details
Active, Not Recruiting

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT02048813

Conditions
Anemia, Chronic Disease, Chronic Lymphocytic Leukemia, +16 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 782 locations
View Trial Details
Active, Not Recruiting

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT05424822

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +15 more
Locations
  • City of Hope Duarte, California, United States
  • Icahn School of Medicine at Mount Sinai New York, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Sarah Cannon Research Institute Nashville, Tennessee, United States
View all 29 locations
View Trial Details
Active, Not Recruiting

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

NCT02981628

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +23 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 157 locations
View Trial Details

Related conditions